Fibroblast Growth Factor 23: A Possible Cause of Left Ventricular Hypertrophy in Hemodialysis Patients

This publication has 38 references indexed in Scilit:

• Fibroblast growth factor-2 and cardioprotection
  Heart Failure Reviews, 2007
• High- but not low-molecular weight FGF-2 causes cardiac hypertrophy in vivo; possible involvement of cardiotrophin-1
  Journal of Molecular and Cellular Cardiology, 2007
• Genetic Ablation of Vitamin D Activation Pathway Reverses Biochemical and Skeletal Anomalies in Fgf-23-Null Animals
  The American Journal of Pathology, 2006
• Effects of Short Daily versus Conventional Hemodialysis on Left Ventricular Hypertrophy and Inflammatory Markers
  Journal of the American Society of Nephrology, 2005
• Changes of the Cardiac Architectures and Functions for Chronic Hemodialysis Patients with Dry Weight Determined by Echocardiography
  Blood Purification, 2004
• Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin
  American Journal of Kidney Diseases, 1999
• Renal replacement therapy in the United States: Data from the United States renal data system
  American Journal of Kidney Diseases, 1995
• Impact of left ventricular hypertrophy on survival in end-stage renal disease
  Kidney International, 1989
• Pulsed Doppler echocardiographic determination of stroke volume and cardiac output: clinical validation of two new methods using the apical window.
  Circulation, 1984
• Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method.
  Circulation, 1977